Cupric Chloride Anhydrous

CHEMBL1200553 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
134.4 g/mol
LogP
Phase
4

An anhydrous form of copper chloride used as a source of copper in intravenous nutrition solutions for patients who cannot eat normally. It helps prevent copper deficiency in these patients.

Masse moléculaire

134,4500 g/mol

TPSA

0,00 Ų

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cl[Cu]Cl

InChI

InChI=1S/2ClH.Cu/h2*1H;/q;;+2/p-2

Molecular Formula

Cl2Cu

HBD / HBA

- / -

Liaisons Rotatives

0

Atomes Lourds

3

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An anhydrous form of copper chloride used as a source of copper in intravenous nutrition solutions for patients who cannot eat normally. It helps prevent copper deficiency in these patients.

Yes, Cupric Chloride Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200553. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 24014. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.